Search results
A lock icon or https:// means you’ve safely connected to the ny.gov website. Share sensitive information only on official, secure websites. Share sensitive information only on official, secure websites.
- About Us
The New York State Psychiatric Institute (NYSPI),...
- Patients and Families
The New York State Psychiatric Institute offers treatment...
- Health Professionals
The New York State Psychiatric Institute offers a wide range...
- Students, Residents, Fellows
The New York State Psychiatric Institute has a wide range of...
- Research
.button-style { background-color: #523178; border: none;...
- Administration
New York State Psychiatric Institute. Joshua A. Gordon, MD,...
- Volunteer Program
The Volunteer Services Program within the Columbia...
- Contact Us
New York, NY 10019 Phone: 212-305-6001: 3 Columbus Circle...
- About Us
1051 Riverside Drive. New York, NY 10032. United States. depression-study@columbia.edu. Our clinic is dedicated to research on mood disorders (major depression and bipolar disorder), borderline personality disorder, prevention of suicide and self-injury, and bereavement.
r/NYStateOfMind: The #1 source for the culture in the New York tri-state area Instagram: @nystateofmindreddit Discord: Discord…
Apr 25, 2023 · It will be embedded within Columbia University’s unique ecosystem of research and clinical services and will draw upon expertise from the Columbia-affiliated New York Genome Center and the New York State Office of Mental Health.
- General Criteria For Admission
- About Our Research
- Leadership Staff
- Current Clinical Trials
Individuals willing to participate in research will be considered for admission to the outpatient services we provide. The following general criteria are also required: 1. A diagnosis of schizophrenia or schizoaffective disorder 2. 18-65 years of age 3. No significant medical problems 4. No recent history of significant violence or self-injurious b...
The Columbia Schizophrenia Research Center (CSRC) supports a number of research studies designed to answer questions about the nature and causes of schizophrenia and optimal treatment approaches. At any given time, we are typically conducting and recruiting for four or more different studies, for which the specifics of eligibility/ineligibility cri...
Joshua Kantrowitz, MD Director, Columbia Schizophrenia Research Center New York State Psychiatric Institute 1051 Riverside Drive, Suite 1800 New York, NY 10032 Joshua.Kantrowitz@nyspi.columbia.edu Marlene Carlson, M.P.H. Clinical Coordinator, Columbia Schizophrenia Research Center New York State Psychiatric Institute 1051 Riverside Drive, Suite 180...
Placebo-Controlled Medication Studies:
D1 Study (CVL-562) Study Title: A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia Brief Description:This is a 6 week long randomized clinical trial (7 study center visits total) which will evaluate four oral doses of a novel experimental medication known as CVL-562 (a dopamine-1 receptor partial agonist) in outpatient subjects aged 18-45 who are within 10 years of onset of schizophrenia, schizoaffective, or schizophreniform disorder. All subjects who...
Assessment Study (does not involve experimental medication):
Reading Study Study Title: Neural Mechanisms of Reading Dysfunction in Schizophrenia Brief Description:This study focuses on reading deficits in first-episode schizophrenia. It is funded by a grant from the National Institute of Mental Health (NIMH). This study addresses how reading deficits affect patients during the earliest phases of the illness (“first episode”) and the immediately preceding period (“clinical high risk”)—especially the relationship between reading disability and social/oc...
Director of the Center for OCD and Related Disorders, New York State Psychiatric Institute, Columbia University; View Dr. Simpson's Publications on PubMed; Follow Dr. Simpson on LinkedIn
Jun 18, 2024 · Brain Health Is Rooted in State of Mind, Finds Study. Having more positive experiences in life is associated with lower odds of developing brain disorders like Alzheimer's disease, slower cognitive decline with age, and even a longer life.
